197 related articles for article (PubMed ID: 11410301)
1. Three-dimensional computed tomography-guided monotherapeutic pararectal brachytherapy of prostate cancer with seminal vesicle invasion.
Koutrouvelis P; Lailas N; Hendricks F; Gil-Montero G; Sehn J; Katz S
Radiother Oncol; 2001 Jul; 60(1):31-5. PubMed ID: 11410301
[TBL] [Abstract][Full Text] [Related]
2. [The brachytherapy with low dose-rate iridium for prostate cancer].
Momma T; Saito S; Ohki T; Satoh H; Toya K; Dokiya T; Murai M
Nihon Hinyokika Gakkai Zasshi; 2000; 91(10-11):657-65. PubMed ID: 11109816
[TBL] [Abstract][Full Text] [Related]
3. Salvage reimplantation in patient with local recurrent prostate carcinoma after brachytherapy with three dimensional computed tomography-guided permanent pararectal implant.
Koutrouvelis P; Hendricks F; Lailas N; Gil-Montero G; Sehn J; Khawand N; Bondy H; Katz S
Technol Cancer Res Treat; 2003 Aug; 2(4):339-44. PubMed ID: 12892517
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer with large glands treated with 3-dimensional computerized tomography guided pararectal brachytherapy: up to 8 years of followup.
Koutrouvelis PG; Lailas N; Katz S; Sehn J; Gil-Montero G; Khawand N
J Urol; 2003 Apr; 169(4):1331-6. PubMed ID: 12629354
[TBL] [Abstract][Full Text] [Related]
5. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
6. Salvage brachytherapy for seminal vesicle recurrence after initial brachytherapy for prostate cancer: a case report.
Hori S; Tanaka N; Asakawa I; Morizawa Y; Hirayama A; Hasegawa M; Konishi N; Fujimoto K
BMC Res Notes; 2014 Oct; 7():760. PubMed ID: 25344831
[TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate.
Petrovich Z; Lieskovsky G; Langholz B; Formenti S; Baert L; Streeter O; Skinner DG
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):139-47. PubMed ID: 9422570
[TBL] [Abstract][Full Text] [Related]
8. Prostate brachytherapy: treatment strategies.
Stone NN; Stock RG
J Urol; 1999 Aug; 162(2):421-6. PubMed ID: 10411050
[TBL] [Abstract][Full Text] [Related]
9. High and intermediate risk prostate cancer treated with three-dimensional computed tomography-guided brachytherapy: 2-8-year follow-up.
Koutrouvelis PG; Gillenwater J; Lailas N; Hendricks F; Katz S; Sehn J; Gil-Montero G; Khawand N
Radiother Oncol; 2003 Jun; 67(3):303-8. PubMed ID: 12865178
[TBL] [Abstract][Full Text] [Related]
10. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
11. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
[TBL] [Abstract][Full Text] [Related]
12. Permanent prostate brachytherapy for Japanese men: results from initial 100 patients with prostate cancer.
Okaneya T; Nishizawa S; Nakayama T; Kamigaito T; Hashida I; Hosaka N
Int J Urol; 2007 Jul; 14(7):602-6. PubMed ID: 17645602
[TBL] [Abstract][Full Text] [Related]
13. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
[TBL] [Abstract][Full Text] [Related]
14. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P
J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen spikes after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
[TBL] [Abstract][Full Text] [Related]
16. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
[TBL] [Abstract][Full Text] [Related]
17. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
18. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study.
Martin T; Baltas D; Kurek R; Röddiger S; Kontova M; Anagnostopoulos G; Dannenberg T; Buhleier T; Skazikis G; Tunn U; Zamboglou N
Strahlenther Onkol; 2004 Apr; 180(4):225-32. PubMed ID: 15057433
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional stereotactic posterior ischiorectal space computerized tomography guided brachytherapy of prostate cancer: a preliminary report.
Koutrouvelis PG
J Urol; 1998 Jan; 159(1):142-5. PubMed ID: 9400457
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen density: a new prognostic indicator for prostate cancer.
Zentner PG; Pao LK; Benson MC; McMahon DJ; Schiff PB
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(1):47-58. PubMed ID: 7690018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
